MYC in cancer: from undruggable target to clinical trials
MYC is among the most infamous oncogenes in cancer. A notable feature that distinguishes it from other common oncogenes is that its deregula…
Tag: Oncogenes
Chromothripsis in cancer
Chromothripsis is a mutational phenomenon in which a single catastrophic event generates extensive rearrangements of one or a few chromosomes. This…
Decoding the functional impact of the cancer genome through protein–protein interactions
Acquisition of genomic mutations enables cancer cells to gain fitness advantages under selective pressure and, ultimately, leads to oncogenic trans…
ALK in cancer: from function to therapeutic targeting
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that acts as an oncogenic driver in solid and haematological malignancies in b…
Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity
Oncogenic protein dosage is tightly regulated to enable cancer formation but how this is regulated by translational control remains unknown. The My…
Targeting ADAR1 with a small molecule for the treatment of prostate cancer
Despite the initial response to androgen signaling therapy, most cases of prostate cancer (PCa) eventually relapse and remain incurable. The specif…